
About Biocartis
Biocartis is a publicly listed company based in Mechelen (Belgium) founded in 2007. Molecular assays for disease detection are developed using proprietary technology. Biocartis has raised $305.3 million across 18 funding rounds from investors including Philips, Johnson & Johnson and KBC Bank & Verzekering. Biocartis has completed 1 acquisition, including Pronota. Its website biocartis.com draws about 11 thousand monthly visits. Biocartis offers products and services including Idylla Platform, Oncology Tests, and Research Assays. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is Biocartis NV.
Company details
Biocartis was founded in 2007 in Mechelen, Belgium, within the molecular diagnostics sector. Proprietary micro-technology platforms are utilized for integrated molecular and immunodiagnostics. Multiplexed detection, quantification, and amplification of bio-analytes such as proteins, nucleic acids, and small molecules are enabled. Analysis of biomolecules linked to disease risk factors, early detection, staging, treatment selection, and monitoring is supported across various applications.
- Headquarters Mechelen, Belgium
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website biocartis.com/en-US
- Social LinkedIn X Facebook YouTube
- Legal Name Biocartis Nv
Products & Services of Biocartis
Biocartis offers a comprehensive portfolio of products and services, including Idylla Platform, Oncology Tests, and Research Assays.
Automated system for rapid molecular testing in oncology labs
Tests for detecting mutations in cancer biomarkers quickly
Assays for exploring new biomarkers in research settings
Apps and channels of Biocartis
its YouTube channel Biocartis has 211 subscribers and 21 videos.
Videos from Biocartis
The most watched videos on Biocartis's YouTube channel, Biocartis (211 subscribers). Click a video to play it here.
More on Biocartis.
Funding Insights of Biocartis
Biocartis has successfully raised a total of $305.3M across 18 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $305.3M
- Total Rounds 18
- First Round $14.9M
(Oct 2009)
- Investors Count 19
Latest 10 of 18 funding rounds of Biocartis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2022 | Post-IPO | – | – | – | |
| May 2021 | $1.7M | Grant | – | – | |
| Dec 2020 | $181.8M | Post-IPO | – | – | – |
| Sep 2020 | $1.41M | Grant | – | – | |
| Jan 2019 | $63.05M | Post-IPO | – | – | – |
| Jan 2018 | $225,081 | Grant | – | – | |
| Nov 2017 | $95.37M | Post-IPO | – | – | – |
| Nov 2016 | $35.02M | Post-IPO | – | – | – |
| Jul 2016 | $60.77M | Debt – Conventional | – | – | |
| Mar 2016 | $272,409 | Grant | – | – |
19 investors in total: 19 institutional.
Investors in Biocartis
Biocartis has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include Philips, Johnson & Johnson and KBC Bank & Verzekering.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity is directed toward private and public companies. | sfpi-fpim.be | Brussels, Belgium | ||
Venture capital firm backed by Johnson & Johnson | jnjinnovation.com/jjdc | Cambridge, United States | ||
Private debt funds are managed across multiple sectors. | 2001 | pmv.eu | Brussels, Belgium | |
Sustainable investing in conscious consumer, energy transition, and healthy living sectors. | 2011 | korys.be | ||
Venture capital fund focused on multiple sectors | valiance-am.com | London, United Kingdom | ||
Healthcare investments are focused on life sciences ventures. | newrhein.com | Philadelphia, USA | ||
Aescap is focused on investing in high-growth biotech companies. | aescap.com | Amsterdam, Netherlands | ||
PE firm focusing on seed and early stage companies based out of Belgium | kbcpe.be | Brussels, Belgium | ||
Early and mid-stage life science focused VC firm investing in the US and Europe | adventls.com | London, United Kingdom |
Investor details for Biocartis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Biocartis
31 people are tracked at Biocartis (9 in leadership, 4 in board & advisors, 18 in team).
| Name | Role | Group |
|---|---|---|
Anthony Green | Executive Vice President, Corporate & Business Development | Leadership |
Randy Polonsky | Chief Financial Officer | Leadership |
Valentina Petrinec | Associate Director Strategic Accounts - Export | Leadership |
Susy Spruyt | Chief People Officer | Leadership |
Ann Claessens | Senior Human Resources Business Partner - L&d Lead | Leadership |
Roger Moody | CEO | Leadership |
Raf Pasmans | Business Director Export | Leadership |
Chris van Haag | Senior Director Global Strategic Partnerships | Leadership |
Paola Valente | Global Head Of Product Management And Product Management Lead Operations | Leadership |
Ann-Christine Sundell | Director | Board & advisors |
Luc Gijsens | Director | Board & advisors |
Christian Reinaudo | Lead Independent Director | Board & advisors |
Herman Verrelst | Chairman | Board & advisors |
Stefanie van Den Bosch | Legal Expert | Team |
Evelien Rondelez | Design And Development Support Manager | Team |
Sarah Saunders | Senior Product Specialist UK And Ireland | Team |
Peter Mousa | Export Business Manager | Team |
Tiruneh Hailemariam | Clinical And Medical Affairs Lead | Team |
Clifford Lynch | Senior Sourcing Manager | Team |
Julie Giraudeau | Key Account Manager | Team |
11 more people are available in the full profile.
Complete people profiles for Biocartis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biocartis
Biocartis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Pronota.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Diagnostics for heart failure, pre-eclampsia, and sepsis are provided. | pronota.com | Ghent, Belgium | 2004 | Sep 2014 | •••• |
Complete acquisition details for Biocartis
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Biocartis
5 dated milestones of Biocartis across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Biocartis is founded.
- Funding First funding round of $14.9M.
- Acquisition Acquires Pronota.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
Web traffic of Biocartis
The website of Biocartis (biocartis.com) receives about 10.5K visits a month and ranks #2,065,137 among all websites worldwide, #2,814 in Biotechnology and Pharmaceuticals.
- Monthly visits10.5K
▲ 9.3% vs previous month
- Unique visitors3.9K
per month
- Global rank#2,065,137
among all websites
- Category rank#2,814
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit2.4
- Average visit44 sec
- DevicesDesktop 41% · Mobile 59%
Websites whose visitors overlap most with Biocartis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
flandersbio.be | flandersbio.be | 100% | – | ||
| abionic.com | 90% | View details | |||
| hartmann.info | 52% | 227.4K | #190,702 | View details | |
| mydiabby.com | 50% | 66.7K | #376,957 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biocartis
Complete news archive for Biocartis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biocartis
Biocartis was founded in 2007 and raised its 1st funding round 2 years after it was founded.
Biocartis is headquartered in Mechelen, Belgium. It is registered at Mechelen, Antwerp, Belgium.
Biocartis is a funded company, having raised a total of $305.3M across 18 funding rounds to date. The company's 1st funding round was a Grant of $272.41K, raised on Oct 2009.
Biocartis was founded in 2007 in Mechelen, Belgium, within the molecular diagnostics sector. Proprietary micro-technology platforms are utilized for integrated molecular and immunodiagnostics. Multiplexed detection, quantification, and amplification of bio-analytes such as proteins, nucleic acids, and small molecules are enabled. Analysis of biomolecules linked to disease risk factors, early detection, staging, treatment selection, and monitoring is supported across various applications.
Biocartis offers Idylla Platform, Oncology Tests, and Research Assays.
Biocartis has made 1 acquisition, including Pronota.
Biocartis has 19 investors. Key investors include Philips, Johnson & Johnson, KBC Bank & Verzekering, Debiopharm, and PMV.
Biocartis operates through Biocartis Nv.
